Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03252587 · ClinicalTrials.gov registry record · Phase 2
An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 363
- Enrollment target
NCT03252587: Completed Phase 2 study, sponsored by Bristol-Myers Squibb.
NCT03252587 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 363 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (173% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03252587, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 363 participants
- Enrollment target
Study Summary
This study will investigate BMS-986165 to assess its effects in participants with systemic lupus erythematosus (SLE).
Primary Outcome
SRI(4) responder is defined as a patient whose disease course fulfills all of the following: 1. A 4-point or greater reduction from baseline in SLEDAI-2K score 2. No new British Isles Lupus Assessment Group (BILAG) A (severe disease activity) and not more than 1 new BILAG B (moderate disease activity) organ domain grade 3. No worsening from baseline in the Physician's Global Assessment of Disease Activity Scale by more than 0.3 points on a 3-point visual analog scale from no disease activity to
Interventions
- OTHER Placebo
- DRUG BMS-986165
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 363 participants |
| Start Date | 2017-09-21 |
| Est. Completion | 2021-10-28 |
| Phase | Phase 2 |
What the finished NCT03252587 record still lists
NCT03252587 is an interventional study that assigns participants to a tested intervention. The registered 363 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (173% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03252587 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03252587 about?
NCT03252587 is a clinical study titled "An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus". This study will investigate BMS-986165 to assess its effects in participants with systemic lupus erythematosus (SLE).
What is the current status of trial NCT03252587?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 363 participants. The study started on 2017-09-21. Estimated completion is 2021-10-28.
What interventions are being tested in trial NCT03252587?
The interventions under investigation include: Placebo (OTHER), BMS-986165 (DRUG).
Who is sponsoring clinical trial NCT03252587?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03252587's enrollment target sits among peer trials
363 122nd of 2000 higher than 1,879 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06472245 · 363 participants · Phase 3
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
- NCT04510597 · 364 participants · Phase 3
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
- NCT05098132 · 364 participants · Phase 1
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
- NCT05330221 · 364 participants · NA
Project 2: ACHIEVE- HF
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI